Antiplatelet therapy alters iron requirements in hemodialysis patients

American Journal of Kidney Diseases

Volumn 36, Issue 1, 2000, Pages 80-87

  Goicoechea, Marian ^a   Caramelo, Carlos ^a,b   Ochando, Antonio ^a   Andrea, Concepción ^a   Garvía, Rosa ^a   Ortiz, Alberto ^a  

^a Section of Nephrology   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Antiplatelet therapy; Autologous fistula; Erythropoietin (EPO); Hemodialysis (HD); Iron requirements; Prosthetic vascular access

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; ERYTHROPOIETIN; FERRIC GLUCONATE; FERRITIN; FERROPROTINA; FERROUS SULFATE; HEPARIN; IRON; IRON LECITHIN COMPLEX; TARDYFERON; TICLOPIDINE;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD VESSEL PROSTHESIS; CARDIOMYOPATHY; CEREBROVASCULAR DISEASE; DRUG INDICATION; FEMALE; HEMODIALYSIS; HUMAN; IRON DEFICIENCY; IRON THERAPY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; POLICY; PRACTICE GUIDELINE; REGRESSION ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; THROMBOSIS PREVENTION; VASCULAR ACCESS;

EID: 0034235215     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2000.8275     Document Type: Article

References (26)

1. Sunder-Plassmann G, Hörl WH: Erythropoietin and iron. Clin Nephrol 47:141-157, 1997
2. Van Wyck DB, Stivelman JC, Ruiz J, Kirlin KF, Katz MA, Odgen DA: Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 35:712-716, 1989
3. Anastassiades EG, Howarth D, Howarth J, Shanks D, Waters HM, Hyde K, Geary CG, Liu Yin JA, Gokal R: Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant 8:846-853, 1993
4. Sunder-Plassman G, Hörl WH: Iron metabolism and iron substitution during erythropoietin therapy. Clin Invest 72:S11-S15, 1994 (suppl)
5. MacDougall IC, Tucker B, Thompson J, Tomson CRV, Baker LRI, Raine AEG: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50:1694-1699, 1994
6. Cook JD, Skikhe BS, Lynch SR, Reusser ME: Estimates of iron sufficiency in the US population. Blood 68:726-731, 1986
7. Bridges KR, Seligman PA: Disorders of iron metabolism, in Handlin RJ, Lux SE, Stossel TP (eds): Blood: Principles and Practice of Hematology. Philadelphia, PA, Lippincott, 1995, pp 1433-1435
8. Tarng D, Huang T, Chen TW: Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy. Am J Nephrol 17:158-164, 1997
9. Eschbach JW: The future of rHuEPO. Nephrol Dial Transplant 10:96-109, 1995
10. Eschbach JW, Cook JD, Scribner BH, Finch CA: Iron balance in hemodialysis patients. Ann Intern Med 87:710-713,1977
11. Gokal R, Millard PR, Weatherall DJ, Callender STE, Ledinghan JGG, Oliver DO: Iron metabolism in haemodialysis patients: A study of the management of iron therapy and overload. Q J Med 48:369-391, 1979
12. Fishbane S, Maesaka JK: Iron management in end-stage renal disease. Am J Kidney Dis 29:319-333, 1997
13. Schaefer RM, Schaefer L: Iron monitoring and supplementation: How do we achieve the best results? Nephrol Dial Transplant 13:9-12, 1998
14. Weinberg ED: Iron withholding: A defense against infection and neoplasia. Physiol Rev 64:65-102, 1984
15. Navarro JF, Teruel JL, Liaño F, Marcen R, Ortuño J: Effectiveness of intravenous administration of Fe-gluconate-Na complex to maintain adequate body iron stores in hemodialysis patients. Am J Nephrol 16:268-272, 1996
16. Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J: Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial. Am J Kidney Dis 33:471-482, 1999
17. Kalantar-Zadeh K, Kleiner M, Dunne E, Ahern K, Nelson M, Koslowe R, Luft FC: Total iron-binding capacity - Estimated transferrin correlates with the nutritional subjective global assessment in hemodialysis patients. Am J Kidney Dis 31:263-272, 1998
18. Fiskerstrand CE, Thompson IW, Burnet ME, Williams P, Anderton JL: Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artif Organs 9:61-63, 1985
19. Grontoft KC, Mulec H, Gutierrez A, Olander R: Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scand J Urol Nephrol 19:55-57, 1985
20. Kobayashi K, Maeda K, Koshikawa S, Kawagugi Y: Antithrombotic therapy with ticlopidine in chronic renal failure patients on chronic maintenance hemodialysis - A multicenter collaborative double-blind study. Thromb Res 20:255-261, 1980
21. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM: Anti-platelet therapy in graft thrombosis: Results of a prospective, randomized, double-blind study. Kidney Int 45: 1477-1483, 1994
22. Akmal M, Sawelson S, Karubian F, Goadallah M: The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF) or receiving dialytic therapy. Clin Nephrol 42:198-202,1994
23. Tschugguel W, Blaicher A, Kramer L, Felfernig M, Jüngling G, Kurz M, Gnant M, Zimpfer M: Platelet disorders in uraemia before and after haemodialysis under the influence of low-dose aspirin. Thromb Res 80:225-233, 1995
24. Baker PN, Williamson JG, Louden KA: Possible low-dose aspirin-induced gastropathy. Lancet 339:550, 1992 (letter)
25. Milutinovic S, Gasparovic V, Milutinovic E, Buturovic-Ponikvar J: Ticlopidine improves dialysis clearance of solutes in uremie patients by reducing blood clotting in dialyser fibers. Int J Artif Organs 16:249-252, 1993
26. Goicoechea M, Martin J, de Sequera P, Quiroga JA, Ortiz A, Carreño V, Caramelo C: Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 54:1337-1343, 1998